Abiomed, Inc.

Report azionario NasdaqGS:ABMD

Capitalizzazione di mercato: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed Crescita futura

Criteri Future verificati 1/6

Informazioni chiave

-2.5%

Tasso di crescita degli utili

-1.98%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavi13.1%
Rendimento futuro del capitale proprio15.09%
Copertura analitica

Low

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.
Seeking Alpha • Sep 28

Abiomed: Correction Offers Good Buying Opportunity

Summary Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace. The company’s OXY-1 System cardiopulmonary support device has strong growth prospect. The company’s revenue will grow at a CAGR of high-single digits in the long term, which will drive the company’s share price significantly higher in the next five years. Abiomed's (ABMD) micro heart pumps enjoy rising demand in the cardiovascular marketplace. I expect the company's Impella range of micro heart pumps will drive the company's long-term revenue growth significantly, and its Impella product pipeline will support long-term revenue growth as well. Long-term growth-oriented investors can buy the company's shares around the current price to maximize their profit. Abiomed develops heart pump products and oxygenation products for patients who are suffering from severe heart disease and in need of hemodynamic support. Its products are used in cath lab by interventional cardiologists and in the heart surgery suite by cardiac surgeons. The company's heart pump products work by improving blood flow and/or performing the pumping function of the heart. Its oxygenation products work by providing sufficient oxygenation to respiratory failure patients. Growth Drivers Impella Heart Pumps Abiomed's Impella micro heart pump product line is its main growth driver. Impella is a percutaneous heart pump that is used to treat CHD (coronary heart disease), and high-risk PCI (percutaneous coronary intervention). Impella has variants which are Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP. These pumps beat competitive products, such as intra-aortic balloon pumps (IABPs) and the TandemHeart device, due to the following reasons: Impella helps CHD and PCI patients maintain proper blood circulation in a better way. Impella offers continued function irrespective of timing or trigger. These pumps offer stability to patients despite the presence of arrhythmias. These pumps can pump up to 2.5 to 6 liters of blood per minute, which provides better cardiac output. According to a report: The heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026. Promising product pipeline, increasing number of product approvals and emerging markets are expected to offer growth opportunities in the market during the forecast period. Due to the strong growth prospects of the heart pump market, Abiomed's revenue will continue to grow rapidly in the next five years. OXY-1 System Abiomed's OXY-1 System, which is a compact cardiopulmonary support system, is the company's another growth driver. The system offers respiratory assistance to patients suffering from cardiogenic shock combined with respiratory failure. The machine's oxygen concentrator and pump provide oxygenation to venous blood, and as a result, patients get significant respiratory support. The device performs well in the competitive environment and beat competitor products such as traditional ECMO (extracorporeal membrane oxygenation) machines due to its capability to provide uniform blood flow and superior respiratory support. I expect the device will support Abiomed's long-term revenue growth which primarily comes from Impella. Competition The heart pump industry is characterized by tremendous competition. Abiomed's competitors in this industry include Abbott Laboratories (ABT), Medtronic (MDT), Edwards Lifesciences (EW), Boston Scientific (BSX), LivaNova (LIVN), and Terumo Corporation (TRUMF). Abiomed competes with these companies on the basis of developing innovative heart pump devices, continuity in new product development, and advanced 24 x 7 hospital support. Abiomed's primary competitive advantage is that its current strategy of developing devices in the area of circulatory care is supported by substantial expertise in developing heart pump devices. As a result, the company's heart pump devices enjoy significant demand in the marketplace. The company intends to continue to use its expertise in developing additional circulatory support devices and making enhancements to existing devices, which will support its future revenue growth. The company's another competitive advantage is that its Impella micro heart pump is the only FDA approved heart pump for high-risk PCI, cardiogenic shock, and right ventricular failure. As a result, Impella and its forthcoming variants will continue to drive Abiomed's revenue growth. First Quarter 2023 Financial Results Abiomed reported first quarter 2023 revenue of $277 million, an increase of 10% year-over-year, compared to $253 million in the prior fiscal year period. Non-GAAP net income per diluted share came in at $1.25, an increase of 13.6% year-over-year, compared to $1.10 in the prior fiscal year period. The company delivered strong results for the first quarter of fiscal 2023. Top line grew driven by robust sales across the U.S., Europe and Japan. The company's heart pump product line is witnessing growing adoption since it addresses the challenge of treating heart disease in multiple emergency patient populations in the cath lab and surgical suite. This is driving the company's revenue growth. The company's bottom line grew driven by strong patient utilization across the three regions mentioned above. Abiomed 2.0, the new Abiomed with unparalleled focus on innovating heart and lung repairing devices amid hindrances such as hospital labor shortages, supply chain constraints and contrast media shortages, will boost the company's top and bottom line growth in the next five years. I expect the company's revenue will grow at a CAGR of high single-digits in this time frame.
Seeking Alpha • Sep 16

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Abiomed (NASDAQ:ABMD) said on Friday it had received two approvals from the U.S. Food and Drug Administration related to clinical research of Impella heart pumps for acute myocardial infarction (AMI) cardiogenic shock or heart attack. The FDA has approved the on-label RECOVER IV trial for AMI cardiogenic shock patients. RECOVER IV is a trial that is designed to to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock. The FDA has also approved and closed Impella’s prospective AMI cardiogenic shock post-approval study, dubbed Recover III. This study gathered real-world evidence on AMI cardiogenic shock patients treated with Impella between 2017–2019, collecting detailed data including stages of cardiogenic shock, cardiac output and timing of implantation.
Seeking Alpha • Aug 03

Abiomed FQ1 2023 Earnings Preview

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue Estimate is $276.46M (+9.4% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • May 17

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a margin of safety, but we recognise the premier product portfolio. Overall, there is a defensive angle for the stock given rate increases, but the valuation is too much of a concern.
Seeking Alpha • Jan 24

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Abiomed is a company with a superb product in the mid-market space while what appears on the surface is an extremely high multiple. While the multiple appears high at first, it does actually reflect the profile of the company on a more normalised basis, where it is currently experiencing headwinds. The secular outlook is obviously intact, but given the high multiple and the unknown length of the medium-term headwinds, it is not an especially compelling opportunity.
Seeking Alpha • Sep 10

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.
Seeking Alpha • Jul 13

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year. Shares are trading at a premium to historical averages and to the peer group, thus balancing the investment case. Nonetheless, we are bullish on ABMD shares and see an investment debate that is skewed in investors' favour. Here, we present all of the necessary moving parts in the investment debate for the benefit of investors' own reasoning.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ABMD - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/20251,488262N/A4462
3/31/20241,265226N/A3603
3/31/20231,144269N/A2993
9/30/20221,074267217251N/A
6/30/20221,056218263298N/A
3/31/20221,032137250285N/A
12/31/20211,003133246293N/A
9/30/2021974149233282N/A
6/30/2021935154248298N/A
3/31/2021848226221275N/A
12/31/2020813200237275N/A
9/30/2020803208246285N/A
6/30/2020798159240282N/A
3/31/2020841203271315N/A
12/31/2019841245257299N/A
9/30/2019820221243284N/A
6/30/2019797258229270N/A
3/31/2019769259208252N/A
12/31/2018737222191238N/A
9/30/2018690190155220N/A
6/30/2018641165142203N/A
3/31/2018594112137193N/A
12/31/201754490103173N/A
9/30/20175059293151N/A
6/30/20174757770125N/A
3/31/20174455265115N/A
12/31/20164154869100N/A
9/30/2016386436992N/A
6/30/201635942N/A92N/A
3/31/201633038N/A77N/A
12/31/2015303126N/A73N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di ABMD diminuiranno nei prossimi 3 anni ( -2.5% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di ABMD diminuiranno nei prossimi 3 anni ( -2.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ABMD diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ABMD ( 13.1% all'anno) crescerà più rapidamente del mercato US ( 11.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ABMD ( 13.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ABMD sarà basso tra 3 anni ( 15.1 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2022/12/24 12:30
Prezzo dell'azione a fine giornata2022/12/21 00:00
Utili2022/09/30
Utili annuali2022/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Abiomed, Inc. è coperta da 21 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Lawrence NeiborBaird
Jan WaldBenchmark Company
Isaac RoGoldman Sachs